期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

尼妥珠单抗联合顺铂对三阴性乳腺癌MDA-MB-231细胞的增殖抑制作用及其机制研究 被引量：6

The Anti-proliferative Effect of Nimotuzumab Combined with Cisplatin on Triple Negative Breast Cancer Cell Line MDA-MB-231 and its Mechanism
原文传递
导出
摘要 [目的]探讨尼妥珠单抗(泰欣生)联合顺铂对三阴性乳腺癌细胞的增殖抑制作用及可能机制。[方法]100μg/ml泰欣生、5μg/ml顺铂单独和联合作用三阴性乳腺癌MDA-MB-231细胞24h、48h后,采用MTT法检测细胞增殖,流式细胞仪检测细胞凋亡,Western Blot技术检测ERK1/2、pERK1/2及BRCA1蛋白表达水平。[结果]泰欣生和顺铂联合作用MDA-MB-231细胞48h后,细胞增殖抑制达82.53%±6.46%,与其余各组相比,差异有显著性(P<0.01)。顺铂和泰欣生单药作用24h,未能明显诱导MDA-MB-231细胞凋亡;但作用48h后顺铂诱导的凋亡率为14.56%,泰欣生组的细胞凋亡仍不明显。泰欣生联合顺铂作用24h未能明显诱导MDA-MB-231细胞凋亡;48h后,细胞凋亡率明显增高,达37.57%,与其余各组相比差异有显著性(P<0.01)。ERK1/2在对照组和各处理组中的表达无变化;pERK1/2在对照组和顺铂组的表达无变化,在泰欣生组和泰欣生+顺铂组的表达明显降低。顺铂和泰欣生单药处理MDA-MB-231细胞后BRCA1蛋白表达量增加,泰欣生与顺铂联合作用后,BRCA1蛋白表达明显降低。[结论]尼妥珠单抗(泰欣生)与顺铂可协同抑制三阴性乳腺癌细胞,其机制可能是降低BRCA1蛋白的表达。
作者 刘杏娥 孙晓东 王晓稼
机构地区 浙江医院 浙江大学医学院附属邵逸夫医院 浙江省肿瘤医院
出处 《肿瘤学杂志》 CAS 2011年第9期678-681,共4页 Journal of Chinese Oncology
关键词 乳腺肿瘤 ER PR HER-2 尼妥珠单抗 顺铂 乳腺癌易感基因1
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1Perou CM,S rlie T,Eisen MB,et al.Molecular portraits of human breast tumours[J].Nature,2000,406(6797):747-752.
  • 2Nanda R.“Targeting”triple-negative breast cancer:the lessons from BRCA1-associated breast cancers[J].Semin Oncol,2011,38(2):254-262.
  • 3刘杏娥,毛伟敏.三阴性乳腺癌的生物学特征及治疗[J].肿瘤学杂志,2009,15(4):352-355. 被引量：3
  • 4Tan DS,Marchio C,Jones RL et al.Triple negative breast cancer:molecular profiling and prognostic impact in adjuvant anthracycline-treated patients[J].Breast Can-cer Res Treat,2008,111(1):27-44.
  • 5Eralp Y,Derin D,Ozluk Y,et al.MAPK overexprssion is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer[J].Ann Oncol,2008,19(4):669-674.
  • 6Yi SY,Ahn JS,Uhm JE,et al.Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype[J].BMC Cancer,2010,10:527.
  • 7Billar JA,Dueck AC,Stucky CC,et al.Triple-negative breast cancers:unique clinical presentations and outcomes[J].Ann Surg Oncol,2010,17(Suppl3):384-390.
  • 8Corkery B,Crown J,Clynes M,et al.Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer[J].Ann Oncol,2009,20(5):862-867.
  • 9Carotenuto P,Roma C,Rachiglio AM,et al.Triple nega-tive breast cancer:from molecular portrait to therapeutic intervention[J].Crit Rev Eukaryot Gene Expr,2010,20(1):17-34.
  • 10Sanchez-Munoz A,Gallego E,de Luque V,et al.Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer[J].BMC Cancer,2010,10:136-144.

二级参考文献35

  • 1Perou CM,Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797):747- 752.
  • 2Rakha EA,EI-Sayed ME,Green AR, et al. Prognostic markers in triple-negative breast cancer[J]. Cancer, 2007, 109 (1): 25-32.
  • 3Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes[J]. Clin Cancer Res, 2007, 13(8): 2329-2334.
  • 4Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basaHike subtype of invasive breast carcinoma[J]. Clin Cancer Res, 2004, 10 (16):5367-5374.
  • 5Srlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J]. Proc Natl Acad Sci USA, 2001, 98(9): 10869-10874.
  • 6Van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome[J]. Am J Pathol, 2002, 161(6): 1991-1996.
  • 7Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms[J]. BMC Genomics, 2006, 7: 96.
  • 8Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets[J]. Proc Natl Acad Sci USA, 2003, 100(14): 8418-8423.
  • 9Reis-Filho JS, Milanezi F, Carvaiho S, et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis[J]. Breast Cancer Res, 2005, 7(6): R1028-R1035.
  • 10Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours[J]. Histopathology, 2006, 49(1): 10-21.

共引文献2

同被引文献105

引证文献6

二级引证文献29

肿瘤学杂志
2011年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部